{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:18:40Z","timestamp":1790108320870,"version":"4.0.1"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2016\/22140\u20137"],"award-info":[{"award-number":["2016\/22140\u20137"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2021\/14534\u20133"],"award-info":[{"award-number":["2021\/14534\u20133"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["307156\/2018\u20134"],"award-info":[{"award-number":["307156\/2018\u20134"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.coph.2023.102355","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T16:01:58Z","timestamp":1678809718000},"page":"102355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: A mini-review of the potential mechanisms"],"prefix":"10.1016","volume":"69","author":[{"given":"Joao Carlos","family":"Ribeiro-Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caio A.M.","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3715-6917","authenticated-orcid":false,"given":"Adriana C.C.","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2023.102355_bib1","doi-asserted-by":"crossref","first-page":"26488","DOI":"10.1074\/jbc.270.44.26488","article-title":"Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide","volume":"270","author":"Rouill\u00e9","year":"1995","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.coph.2023.102355_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1210\/endo.130.1.1309325","article-title":"Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells","volume":"130","author":"Fehmann","year":"1992","journal-title":"Endocrinology"},{"key":"10.1016\/j.coph.2023.102355_bib3","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.2337\/diabetes.48.12.2270","article-title":"Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats","volume":"48","author":"Xu","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.coph.2023.102355_bib4","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/361362a0","article-title":"Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)","volume":"361","author":"Holz","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.coph.2023.102355_bib5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/ncpendmet0017","article-title":"Biologic actions and therapeutic potential of the proglucagon-derived peptides","volume":"1","author":"Drucker","year":"2005","journal-title":"Nat Clin Pract Endocrinol Metabol"},{"key":"10.1016\/j.coph.2023.102355_bib6","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","article-title":"Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects","volume":"44","author":"Deacon","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.coph.2023.102355_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40256-020-00423-z","article-title":"Blood pressure-lowering effect of newer antihyperglycemic agents (SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors)","volume":"21","author":"Liakos","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.coph.2023.102355_bib8","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2023.102355_bib9","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/00004872-200306000-00012","article-title":"Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats","volume":"21","author":"Yu","year":"2003","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.coph.2023.102355_bib10","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nm.3128","article-title":"GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure","volume":"19","author":"Kim","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2023.102355_bib11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bbrc.2009.01.003","article-title":"Exendin-4 has an antihypertensive effect in salt-sensitive mice model","volume":"380","author":"Hirata","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.coph.2023.102355_sref12","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/HYPERTENSIONAHA.120.14868","article-title":"Endogenous activation of glucagon-like peptide-1 receptor contributes to blood pressure control","volume":"76","author":"Martins","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.coph.2023.102355_sref13","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49364-x","article-title":"Central glucagon-like peptide-1 receptor signaling via brainstem catecholamine neurons counteracts hypertension in spontaneously hypertensive rats","volume":"9","author":"Katsurada","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2023.102355_bib14","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary Syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2023.102355_bib15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2023.102355_bib16","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2023.102355_bib17","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1056\/NEJMoa1612917","article-title":"Once-weekly exenatide and cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2023.102355_bib18","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2023.102355_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2023.102355_bib20","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2023.102355_bib21","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with Efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2023.102355_bib22","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1111\/j.1460-9568.1995.tb00650.x","article-title":"Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites","volume":"7","author":"G\u00f6ke","year":"1995","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.coph.2023.102355_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2337\/dbi18-0045","article-title":"Glucagon-like peptide 1 in the brain: where is it coming from, where is it going?","volume":"68","author":"Daniels","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.coph.2023.102355_sref24","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCRESAHA.121.319874","article-title":"GLP1R attenuates sympathetic response to high glucose via carotid body inhibition","volume":"130","author":"Pauza","year":"2022","journal-title":"Circ Res"},{"key":"10.1016\/j.coph.2023.102355_bib25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neuroscience.2016.12.039","article-title":"Direct effects of glucose, insulin, GLP-1, and GIP on bulbospinal neurons in the rostral ventrolateral medulla in neonatal wistar rats","volume":"344","author":"Oshima","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.coph.2023.102355_bib26","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1113\/EP085075","article-title":"Crosstalk between the renal sympathetic nerve and intrarenal angiotensin II modulates proximal tubular sodium reabsorption","volume":"100","author":"Pontes","year":"2015","journal-title":"Exp Physiol"},{"key":"10.1016\/j.coph.2023.102355_bib27","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1152\/physrev.00039.2019","article-title":"Carotid body chemoreceptors: physiology, pathology, and implications for health and disease","volume":"101","author":"Iturriaga","year":"2021","journal-title":"Physiol Rev"},{"key":"10.1016\/j.coph.2023.102355_bib28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejphar.2017.05.054","article-title":"Attenuated diuresis and natriuresis in response to glucagon-like peptide-1 in hypertensive rats are associated with lower expression of the glucagon-like peptide-1 receptor in the renal vasculature","volume":"811","author":"Savignano","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coph.2023.102355_bib29","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/HJH.0000000000000480","article-title":"Protein kinase C\u03b2 mediates downregulated expression of glucagon-like peptide-1 receptor in hypertensive rat renal arteries","volume":"33","author":"Liu","year":"2015","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.coph.2023.102355_bib30","series-title":"GLP-1-induced renal vasodilation in rodents depends exclusively on the known GLP-1 receptor and is lost in pre-hypertensive rats","author":"Jensen","year":"2020"},{"key":"10.1016\/j.coph.2023.102355_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s002400050096","article-title":"LLC-PK1 cells as a model system to study proximal tubule transport of water and other compounds relevant for renal stone disease","volume":"27","author":"Verkoelen","year":"1999","journal-title":"Urol Res"},{"key":"10.1016\/j.coph.2023.102355_sref32","article-title":"Role of renal sympathetic nerves in GLP-1 (Glucagon-Like peptide-1) receptor agonist exendin-4-mediated diuresis and natriuresis in diet-induced obese rats","volume":"10","author":"Liu","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.coph.2023.102355_bib33","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1681\/ASN.2006070778","article-title":"Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db\/db mice","volume":"18","author":"Park","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.coph.2023.102355_bib34","first-page":"1029","article-title":"Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure","volume":"6","author":"Dos Santos","year":"2013","journal-title":"Circulation: Heart Fail"},{"key":"10.1016\/j.coph.2023.102355_bib35","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/HYPERTENSIONAHA.112.195115","article-title":"Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism","volume":"60","author":"Liu","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.coph.2023.102355_bib36","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","article-title":"Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways","volume":"117","author":"Ban","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2023.102355_sref37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","article-title":"Endothelial GLP-1 (Glucagon-Like peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension","volume":"40","author":"Helmst\u00e4dter","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.coph.2023.102355_bib38","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.coph.2023.102355_bib39","doi-asserted-by":"crossref","first-page":"F867","DOI":"10.1152\/ajprenal.00527.2014","article-title":"Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow","volume":"308","author":"Jensen","year":"2015","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.coph.2023.102355_bib40","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.abb.2008.08.001","article-title":"GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP","volume":"478","author":"Green","year":"2008","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.coph.2023.102355_bib41","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1161\/ATVBAHA.110.222653","article-title":"Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels","volume":"32","author":"Ha","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.coph.2023.102355_bib42","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejphar.2013.10.033","article-title":"Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of L-NAME in rats: role of GLP-1 and GLP-1 receptor","volume":"720","author":"Abd El Motteleb","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coph.2023.102355_bib43","doi-asserted-by":"crossref","first-page":"E947","DOI":"10.1152\/ajpendo.00400.2015","article-title":"Exenatide exerts direct protective effects on endothelial cells through the AMPK\/Akt\/eNOS pathway in a GLP-1 receptor-dependent manner","volume":"310","author":"Wei","year":"2016","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.coph.2023.102355_bib44","article-title":"Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS\/sGC\/PKG pathways","volume":"6","author":"Lee","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2023.102355_bib45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/aps.2011.149","article-title":"Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells","volume":"33","author":"Ding","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.coph.2023.102355_bib46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mce.2011.03.007","article-title":"Glucagon-like peptide 1 protects microvascular endothelial cells by inactivating the PARP-1\/iNOS\/NO pathway","volume":"339","author":"Liu","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.coph.2023.102355_bib47","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.2337\/db14-0976","article-title":"Exenatide protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans","volume":"64","author":"Koska","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.coph.2023.102355_bib48","doi-asserted-by":"crossref","first-page":"E1289","DOI":"10.1152\/ajpendo.00373.2007","article-title":"Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride","volume":"293","author":"Basu","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.coph.2023.102355_sref49","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.abb.2019.07.008","article-title":"Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activation","volume":"671","author":"Luo","year":"2019","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.coph.2023.102355_bib50","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.atherosclerosis.2011.12.039","article-title":"The glucagon-like peptide 1 analog liraglutide reduces TNF-\u03b1-induced oxidative stress and inflammation in endothelial cells","volume":"221","author":"Shiraki","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.coph.2023.102355_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097554","article-title":"Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism","volume":"9","author":"Krasner","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2023.102355_bib52","doi-asserted-by":"crossref","first-page":"C164","DOI":"10.1152\/ajpcell.00249.2014","article-title":"Exendin-4 promotes endothelial barrier enhancement via PKA- and Epac1-dependent Rac1 activation","volume":"308","author":"Li","year":"2015","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.coph.2023.102355_sref53","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2020.111005","article-title":"Glucagon-like peptide 1 treatment reverses vascular remodelling by downregulating matrix metalloproteinase 1 expression through inhibition of the ERK1\/2\/NF-\u03baB signalling pathway","volume":"518","author":"Fan","year":"2020","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.coph.2023.102355_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2017.10.085","article-title":"Exendin-4 improves cardiovascular function and survival in flow-induced pulmonary hypertension","volume":"155","author":"Roan","year":"2018","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.coph.2023.102355_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137960","article-title":"Exendin-4 prevents vascular smooth muscle cell proliferation and migration by angiotensin II via the inhibition of ERK1\/2 and JNK signaling pathways","volume":"10","author":"Nagayama","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2023.102355_bib56","doi-asserted-by":"crossref","first-page":"F355","DOI":"10.1152\/ajprenal.00729.2010","article-title":"Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1","volume":"301","author":"Crajoinas","year":"2011","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.coph.2023.102355_bib57","doi-asserted-by":"crossref","first-page":"F963","DOI":"10.1152\/ajprenal.00259.2012","article-title":"Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice","volume":"303","author":"Rieg","year":"2012","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.coph.2023.102355_bib58","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1210\/jc.2003-031403","article-title":"Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men","volume":"89","author":"Gutzwiller","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2023.102355_bib59","doi-asserted-by":"crossref","first-page":"E664","DOI":"10.1210\/jc.2012-3855","article-title":"Glucagon-like peptide-1 (GLP-1): effect on kidney\u00a0hemodynamics and renin-angiotensin-aldosterone system in healthy men","volume":"98","author":"Skov","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2023.102355_bib60","doi-asserted-by":"crossref","first-page":"E744","DOI":"10.1152\/ajpendo.00518.2015","article-title":"Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy","volume":"310","author":"Asmar","year":"2016","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.coph.2023.102355_bib61","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/969","article-title":"Renal and intestinal absorptive defects in mice lacking the NHE3 Na+\/H+ exchanger","volume":"19","author":"Schultheis","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.coph.2023.102355_bib62","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/HYPERTENSIONAHA.119.13094","article-title":"Proximal tubule\u2013specific deletion of the NHE3 (Na\u00a0+\/H\u00a0+ exchanger 3) promotes the pressure-natriuresis response and lowers blood pressure in mice","volume":"74","author":"Li","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.coph.2023.102355_bib63","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1152\/ajprenal.00394.2015","article-title":"The physiological role of glucagon-like peptide-1 in the regulation of renal function","volume":"310","author":"Farah","year":"2016","journal-title":"Am J Physiol Ren Physiol"},{"issue":"1-3","key":"10.1016\/j.coph.2023.102355_bib64","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.regpep.2006.12.016","article-title":"Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells","volume":"141","author":"Schlatter","year":"2007","journal-title":"Regul Pept"},{"key":"10.1016\/j.coph.2023.102355_bib65","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.23.1_supplement.602.12","article-title":"The inhibitory effect of the glucagon-like peptide-1 analog exendin-4 on NHE3 activity in proximal tubule cells is mediated by both PKA and EPAC signaling pathways","volume":"23","author":"Carraro-Lacroix","year":"2009","journal-title":"Faseb J"},{"key":"10.1016\/j.coph.2023.102355_bib66","doi-asserted-by":"crossref","first-page":"46671","DOI":"10.1074\/jbc.M106897200","article-title":"Association of Na+-H+ exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule","volume":"276","author":"Girardi","year":"2001","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.coph.2023.102355_bib67","doi-asserted-by":"crossref","first-page":"C1238","DOI":"10.1152\/ajpcell.00186.2004","article-title":"Role of dipeptidyl peptidase IV in regulating activity of Na\u00a0+\/H+ exchanger isoform NHE3 in proximal tubule cells","volume":"287","author":"Girardi","year":"2004","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.coph.2023.102355_bib68","doi-asserted-by":"crossref","first-page":"F414","DOI":"10.1152\/ajprenal.00174.2007","article-title":"Dipeptidyl peptidase IV inhibition downregulates Na(+)-H(+) exchanger NHE3 in rat renal proximal tubule","volume":"294","author":"Girardi","year":"2008","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.coph.2023.102355_bib69","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.mvr.2012.06.008","article-title":"Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A","volume":"84","author":"Ishibashi","year":"2012","journal-title":"Microvasc Res"},{"key":"10.1016\/j.coph.2023.102355_bib70","doi-asserted-by":"crossref","first-page":"C768","DOI":"10.1152\/ajpcell.00191.2016","article-title":"Angiotensin II counteracts the effects of cAMP\/PKA on NHE3 activity and phosphorylation in proximal tubule cells","volume":"311","author":"Crajoinas","year":"2016","journal-title":"Am J Physiol Cell Physiol"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489223000085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489223000085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:57:34Z","timestamp":1761461854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489223000085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":70,"alternative-id":["S1471489223000085"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2023.102355","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: A mini-review of the potential mechanisms","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2023.102355","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102355"}}